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Abstract 
Background: Both HIV infection and combined antiretroviral therapy (cART) are 
associated with metabolic and fat distribution changes, as well as cardiovascular 
disease. Methods: A cross-sectional study was performed in 572 HIV1-infected 
Caucasian adults on cART, who were grouped according to four different groups of fat 
distribution. Cardiovascular disease risk was measured using Framingham-CHD, 
SCORE and ASCVD scoring systems and the agreement between them was evaluated. 
The concordance between metabolic syndrome and cardiovascular disease risk scores 
was assessed.  Results: Among 572 HIV-infected patients, 70% were male, 31.29% had 
isolated central fat accumulation, 26.40% had isolated lipoatrophy, 26.05% registered 
mixed forms of lipodystrophy, and 16.26% of the patients had no lipodystrophy. The 
prevalence of metabolic syndrome in our sample was 49.22%. Approximately 70% of 
patients with mixed forms of lipodystrophy (vs 30% of non-lipodystrophic patients) had 
this pathology. Independently of which scoring system was used, we found a high 
prevalence of high to very high categories of cardiovascular risk. Patients with mixed 
forms of lipodystrophy had higher cardiovascular risk, according to the Framingham 
risk score. Agreement between cardiovascular disease risk scores and between these and 
metabolic syndrome was not very good (kappa value < 0.50; p<0.001). However, when 
comparing lower and higher risk categories, a high proportion of the sample agreed in 
such conditions, which was being more evident when comparing the FHS to the 
ASCVD risk score. Conclusions: Patients had a high percentage of 10-year 
cardiovascular disease risk, independent of which scoring system was used, or the group 
of fat distribution. Patients with mixed forms of lipodystrophy, and also those with no 
lipodystrophy are at higher and lower risk of having cardiovascular disease, 
respectively.  
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Background 
HIV infection was a prevalent cause of premature death. At present, the emergence of 
cART increased life expectancy and reduced morbidity and mortality in these patients, 
turning HIV into a manageable chronic disease [1-2]. cART’s side effects include, 
among other: metabolic changes, such as lipid disorders; insulin resistance; changes in 
glucose metabolism, and; hypertension. Changes in fat distribution and metabolic 
syndrome (MS) are clearly associated with HIV patients [3-4]. Cardiovascular disease 
(CVD) is also a major concern for the long-term use of cART. Additionally, the virus 
itself triggers many pathways that end up promoting metabolic disorders, immune 
processes and chronic inflammation. All this culminates in metabolic and organic 
diseases, including endothelial dysfunction, which accelerates the atherosclerotic 
process, and therefore increases the risk of cardiovascular disease [5-6]. As it is an 
active endocrine organ, the adipose tissue may also allow metabolic and inflammatory 
processes to take place, leading to the emergence of atherosclerosis as well [7]. On top 
of this, risk factors such as obesity, smoking, hypertension, dyslipidemia and diabetes 
could already have been established before HIV was diagnosed, or they may arise 
independently of the infection and the use of medication. These risk factors are highly 
prevalent in patients with HIV, making this population vulnerable to CVDs. [8-11]. 
Factors such as sedentarism, diet, and drug addiction may boost this problematic as 
well. Despite involving multifactorial mechanisms, the traditional risk factors are 
significant determinants of CVD risk in HIV-infected patients. The DAD study found a 
growing relative CHD risk with increased duration of cART, due in part to traditional 
risk factors. Nevertheless, the absolute CHD rates were still low [12]. CVD assessment 
is therefore of great importance for these patients.  
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Study aims 
The primary goal of this study was to compare different CVD risk scores and predictors 
in HIV-infected patients under cART, according to different fat distribution groups.  
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Methods 
Patient selection and study design 
A cross-sectional study was performed in 572 HIV-infected Caucasian adults, 402 men, 
and 170 women, between 30 and 79 years old, who were, at the moment of the first 
visit, on cART. HIV-1 patients were included from the Endocrinology Outpatient 
Department of São João Hospital, who had been referred from the Infectious Diseases 
Clinic.  
The study agreement was approved by the Ethics Committee for Health of Hospital São 
João and every patient provided written informed consent.  
Clinical assessment 
For each patient, the following data was collected, using a standardized protocol: age 
and gender; duration of HIV infection; cART in years; CD4+ cell count, and; viral load. 
Further date was collected for: alcohol; smoking (active, past, never); personal history 
of CVD; family history of CVD; clinical history of hypertension; diabetes; use of 
antidiabetics; insulin, and; anti-hypertensive drugs. Resting blood pressure, after 5 
minutes seated was measured, with the elbow flexed at the heart, using a standard 
aneroid sphygmomanometer, with the cuff on the upper right arm. Two blood pressure 
readings were taken, and the mean of the two readings was calculated. Data was also 
collected for lipid assessment: total cholesterol (TC); low-density cholesterol (LDL); 
high-density cholesterol (HDL); triglycerides (TG), and; use of lipid-lowering drugs 
(statins, fibrates). In addition height (measured in standing position using a wall 
stadiometer - Holtain Limited Crymych, Dyfed®), weight (measured using TANITA - 
Tanita®, model TBF 300), body mass index (BMI) [calculated as weight divided by 
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height squared (kg/m2)], and waist and hip circumference were also evaluated. Clinical 
lipodystrophy (CL) and central fat accumulation or abdominal prominence (AP), were 
defined as has been previously described [13-14].  Central fat accumulation or 
abdominal prominence was determined by using the latest International Diabetes 
Federation (IDF) criteria [15] for the metabolic syndrome, based on a waist 
circumference of ≥94 cm for men, and 80 cm for women. Four different groups were 
characterized:  Group 1 - no lipodystrophy (no clinical lipoatrophy nor abdominal 
prominence); group 2 - isolated central fat accumulation (no clinical lipoatrophy and 
with abdominal prominence); group 3 - isolated lipoatrophy (with clinical lipoatrophy 
and without abdominal prominence), and; group 4 - mixed forms of lipodystrophy (with 
clinical lipoatrophy and with abdominal prominence). All clinical assessments were 
performed by the same practitioner (PF). 
Laboratory analysis 
A venous blood sample was taken after a 12-hour overnight fast and all the samples 
were analyzed at the central laboratory of our hospital. Plasma glucose, total 
cholesterol, HDL cholesterol, and triglycerides were determined, using automatic 
standard routine enzymatic methods. The CD4+ cell count was determined by flow 
cytometry, and plasma RNA-VIH was measured by a quantitative reverse transcriptase 
polymerase chain reaction, which had a lower limit of detection of 50 copies/mL. 
Diabetes definition 
Diabetes was defined if two consecutive measurements of fasting plasma glucose were 
≥126 mg/dL and if 2h plasma glucose was ≥200 mg/dL during the oral glucose 
tolerance test (OGTT). 
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Cardiovascular risk evaluation  
A 10-year cardiovascular risk score was performed, using the following CVD risk 
scores, after excluding all of those with missing essential data fom risk score calculation 
(Table 1): 
-   The Framingham Heart Study risk prediction score for coronary heart disease (FHS-
CHD) [16] (n=527). Personal history of CVD and diabetes was included for the very 
high risk category.  
- The European SCORE [17] (n=353) - a web-based tool was used, using the low-risk 
chart, according to Portugal’s guidelines [18]; patients were excluded if they were under 
40, or over 65 years old, with CT > 305 mg/dL, or SBP > 180 mmHg. Personal history 
of CVD and diabetes with other CVD risk factors was included for the very high risk 
category (130/353). 
-    The 10-year ASCVD score – from the American College of Cardiology and the 
American Heart Association (ACC/AHA) [19] (n=281), which is a web-based tool [20]; 
patients were excluded if they were under 40 or above 79 years old, with a history of 
CVD, LDL  ≥ 190 mg/dL, CT < 130 mg/dL, and CT > 320 mg/dL.  94 of the excluded 
patients had personal CVD history and/or an LDL ≥ 190 mg/dL.  
Metabolic syndrome 
We used the latest International Diabetes Federation (IDF) definition for the diagnosis 
of Metabolic Syndrome [15], which has been described above. At least three of the five 
criteria must be present to designate metabolic syndrome (central obesity, hypertension, 
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elevated fasting glucose, low high-density lipoprotein or hypertriglyceridemia) (Table 
1). 
Statistical analysis 
Data were presented as mean and standard deviation (SD) for quantitative variables 
when normally distributed. When the variable distribution was different from the 
normal, this was expressed as the median and respective interquartile range. For the 
comparison between quantitative variables and the four groups of fat distribution an 
analysis of variance, or the Kruskall-Wallis test was used, as appropriate. Categorical 
variables were described as counts and proportions, and were compared using the chi-
square or Fisher’s exact test. Agreement between cardiovascular risk scores was 
assessed by observed agreement, using Cohen’s kappa (ĸ) statistics. The level of 
agreement was considered poor if ĸ = 0.20, fair if ĸ = 0.21-0.40, moderate if ĸ = 0.41-
0.60, substantial if ĸ = 0.61-0.80, and very good if ĸ >0.80. Statistical analysis was 
performed using the SPSS version 21.0 software (SPSS Inc., Chicago, Illinois, USA). 
All probabilities were two tailed and p values <0.05 were regarded as significant. 
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Results 
We evaluated 572 HIV-infected patients (402 men and 170 women) on cART. We 
observed that 31.3% had isolated central fat accumulation, 26.4% demonstrated isolated 
lipoatrophy, 26.1% mixed forms of lipodystrophy, and 16.3% of the patients had no 
lipodystrophy (Group 1).  Table 2 describes the sample, according to the four groups of 
fat distribution. The whole sample analyzed is smaller in some characteristics due to 
missing data.  
Patient characteristics 
The mean age of our sample varied from 43.8 to 52.7 years, with non-lipodystrophic 
patients being younger. Those with mixed forms of lipodystrophy were older. Our 
patients were predominantly male (70.3%) and the discrepancy between genders was 
higher among those with no lipodystrophy and isolated lipoatrophy. Almost half of 
patients with isolated central fat accumulation were females.  
Patients with no lipodystrophy and isolated central fat accumulation had the lowest HIV 
infection, as well as cART duration, CD4+ cell count and viral load suppression. Those 
with isolated lipoatrophy and mixed forms of lipodystrophy had been HIV positive on 
cART for more than 8 years, with higher CD4+ cell count, and a viral load suppression 
of above 86%. No differences were found between groups on IP/NNRTI intake, 
whereas NRTI intake was highest in patients with isolated lipoatrophy.  
Patients with no lipodystrophy had less than 16%, 10%, and 8% of lipid-lowering, anti-
hypertensive, and oral antidiabetic drug use, respectively. Few patients were 
hypertensive, and they had lower TG, glucose and HbA1c medians, a higher HDL 
mean, normal BMI, and two times less the proportion of metabolic syndrome than those 
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with isolated central fat accumulation and mixed forms of lipodystrophy. On the other 
hand, patients with no lipodystrophy were the group that had the highest proportion of 
male individuals (>78%), and the highest level of active smokers (>50%), aside with 
Group 3 (isolated lipoatrophy). Conversely, patients with mixed forms of lipodystrophy 
had a higher burden of traditional CVD risk factors, except for active smokers (<30%). 
These were older, and used more lipid lowering, oral antidiabetic and antihypertensive 
drugs. Almost 50% of them were hypertensive. Anthropometric measures were the 
highest in this group and the isolated central fat accumulation group, with an 
overweight BMI mean. Glucose and HbA1c were also highest in this group, and 
metabolic syndrome was more than two times higher than that of non-lipodystrophic 
patients. When comparing the isolated central fat accumulation group with the isolated 
lipoatrophy group, active smoking was two times higher in the latter, and hypertension 
was more prevalent in the isolated central fat accumulation group. BMI, waist and hip 
circumference, as well as TC, LDL, and HDL were lower in those with isolated 
lipoatrophy, and higher in those with isolated central fat accumulation. However, TG 
median was highest in patients with isolated lipoatrophy. Metabolic syndrome 
prevalence of those with isolated central fat accumulation is similar to that of mixed 
forms of lipodystrophy group. Those with isolated lipoatrophy had much lower MS 
prevalence, with non-lipodystrophic patients having the lowest.  
Seven to eight patients with no lipodystrophy and isolated lipoatrophy had a personal 
history of CVD, whereas 20 to 22 of those with isolated central fat accumulation and 
mixed forms of lipodystrophy had already experienced a CVD event.  
With regard to CDC classification, C category was present in 42.9% of our sample, with 
A category in 55.2%. Around 40% of patients had alcohol intake and a familiar history 
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of CVD. Diabetes was present in 19.6% to 29.7% of our sample, being lower in non-
lipodystrophic patients, and higher in mixed forms of the lipodystrophy group. 
However, no significant difference was found between groups with respect to these last 
mentioned variables.   
Cardiovascular disease risk scores 
Our sample has a high prevalence of high to very high risk categories, independent of 
which scoring system was used. FHS and ASCVD categorize patients as high/very high 
risk more frequently than the SCORE system does (>50% vs. approximately 40%, 
respectively) (Table 3). 
This high prevalence of higher risk categories remains, despite which group we are 
observing. Nonetheless, a lower proportion of these categories exist in patients with no 
lipodystrophy, whereas the highest is found in patients with mixed forms of 
lipodystrophy. In every group, the SCORE equation classifies most individuals as being 
of low/moderate CVD risk. On the other hand, ASCVD is the system which classified 
most patients in the high to very high risk categories (except in mixed forms of 
lipodystrophy group, where the FHS scoring system classified most individuals in these 
higher categories – approximately 70%).  However, statistically significant differences 
between groups were only found when using FHS (p<0.001) (Table 2). Patients with 
mixed forms of lipodystrophy are at higher CHD risk, according to FHS. On the other 
hand, patients with no lipodystrophy were mostly categorized as having low/moderate 
CHD.  
Agreement of metabolic syndrome and CVD risk scores (Table 4) 
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Metabolic syndrome was compared to very high risk categories in FHS, SCORE and 
ASCVD. Agreement between MS and CVD risk scores was fair, with similar kappa 
values between each pair (0.342-0.385, p<0.001). 58.9%, 58.0%, and 72.4% individuals 
had metabolic syndrome and a “very high” risk category within FHS, SCORE or 
ASCVD, respectively.  
Agreement of cardiovascular disease risk scores  
For the whole sample, the overall observed agreement between scores was not very 
good (range: 0.095-0.475). The best kappa coefficient was observed in the comparison 
between ASCVD vs. FHS (Table 5). Observing risk categories individually, the “very 
high risk” category was the one with the best agreement, regardless of the scoring 
system used. Most patients classified as being “moderate” FHS, are also “moderate” 
SCORE or ASCVD. However, 73.3% of “high risk” FHS were classified as being 
“low”/“moderate” SCORE, and 50% as “moderate” ASCVD. “Very high” risk category 
classified by FHS agreed in 71.6% of cases, in the high/very high SCORE categories 
and with high risk category in 95.6% using ASCVD. Finally, between SCORE and 
ASCVD, 53.9% of moderate SCORE are classified as being high/very high ASCVD. 
However, when considering the “very high” SCORE, 76.4% are also “very high” 
ASCVD.   
Agreement between CVD risk scores in different fat distribution groups prevailed about 
the same as the whole sample. The agreement was poor (k<0.20) in FHS vs. SCORE 
and fair (0.21-0.40) in FHS vs. ASCVD and SCORE vs. ASCVD. The isolated central 
fat accumulation group in SCORE vs. ASCVD was the only one in which the agreement 
was substantial (k=0.487; p<0.001) (Data not shown). 
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Discussion 
Our sample had a relatively high duration of HIV infection; all of whom were on cART, 
being predominantly male. A high prevalence of familiar history of CVD was present, 
and our mean age is considered as a CVD risk factor. Lipodystrophy was present in the 
majority of patients, and metabolic syndrome was diagnosed in almost half of our 
sample. We may already expect that there will be a high CVD risk.  
Furthermore, a high burden of traditional risk factors was found: 24.25% were diabetic, 
35.26% were hypertensive, and 28 to 57% were active smokers. TC and LDL means, 
and TG median were all above optimal. In addition, BMI mean was high in some of the 
described groups.  
When comparing results to similar studies, samples with HIV and cART duration, as 
well as being predominantly male were considered. Only a few previous studies had 
such a high prevalence of metabolic syndrome, hypertension, or diabetes. This may be 
explained by the fact that this sample was obtained from an Endocrinology Department 
database, and therefore presented such results.  However, 40.8% of an Italian study [21], 
and 36.8% of the DAD study [22] had lipodystrophy.  
The high smoking rates present in our study, as well as in other studies are of great 
importance, as it is a major CVD risk factor. Our results were not consistent with the 
DAD study’s finding, in that smoking rates decreased with cART duration [22]. Patients 
with isolated lipoatrophy had the highest cART duration and also, the highest 
prevalence of active smoking. Nevertheless, it is interesting to observe that patients with 
a higher proportion of active smoking are those that have fewer remaining traditional 
risk factors. These results may suggest that an effort is being made to alert patients with 
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higher burden of other CVD risk factors to stop smoking. In fact, a higher percentage of 
former smokers exist for patients with isolated central fat accumulation and mixed 
forms of lipodystrophy. On the other hand, approximately 50% of the individuals of the 
latter groups had never smoked at all.  
Our study is one of the first to evaluate whether there is a higher CVD risk among 
different classes of lipodystrophy. Taking into consideration the higher burden of CVD 
risk factors in patients with isolated central fat accumulation and mixed forms of 
lipodystrophy, these are expected to have higher CVD risk. These two groups differ 
essentially for HIV and cART duration, being higher in the second group. Isolated 
central fat accumulation may already be present before HIV diagnosis, and may 
influence metabolic parameters by itself, without much HIV and cART influence. It 
may explain why, despite lower HIV and cART duration, there is a similar burden of 
risk factors in this last group of individuals when compared to patients with mixed 
forms of lipodystrophy. Patients with isolated lipoatrophy have higher HIV and cART 
duration, but fewer CVD risk factors. The type of fat distribution is probably associated 
with certain risk parameters.  
As expected, a high percentage of our sample is subject to a high risk of CVD. High to 
very high risk categories were found in an elevated proportion of the sample, 
independently of which score system was used,  
Most similar studies had a much lower incidence of higher risk categories, except for 
Begovac, J., et al. [23], which presented 58.3% of individuals having >10% risk, using 
FH-CVD. This last study also had a high prevalence of traditional risk factors. In a 
Swiss study [24] with more than 8.000 HIV-infected individuals, 2.757 were male, aged 
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over 40. For this subset of patients, CVD risk factors were highly prevalent and 38.5% 
had higher FH-CHD categories.  
Differences were found between groups when using the FHS, but not with SCORE or 
ASCVD. Framingham high/very high risk category proportion was almost two times 
higher in patients with mixed forms of lipodystrophy vs. non-lipodystrophic patients 
(67.6% vs. 41.8%, respectively). These results were already expected, when analyzing 
each group’s characteristics. However, groups with isolated central fat accumulation 
have approximately 20% less individuals than the former group, and the prevalence of 
higher categories is similar to that of the isolated lipoatrophy group (50.3 vs 49.3, 
respectively). The isolated lipoatrophy group has a higher mean age, a greater 
percentage of male individuals, higher HIV and cART duration, and CD4 cell count, a 
higher percentage of undetectable viral load, twice as many active smokers, higher TG 
median and fibrate use, and insulin intake, and lower HDL. This counteracts with a 
higher prevalence of personal CVD disease, hypertension, and metabolic syndrome in 
patients with isolated central fat accumulation. Statin, oral antidiabetic and anti-
hypertensive use was also highest in this group, as well as all anthropometric measures, 
glucose median, and TC and LDL means. These two groups are at similar CHD risk, 
despite different contributing factors.   
Agreement between CVD risk scores was not very good in any of the risk scoring 
systems that were compared (FHS/SCORE, FHS/ASCVD, ASCVD/SCORE). A critical 
analysis has to be made when looking at kappa coefficients, as this agreement indicator 
is based on all the categories taken together. When observing each category 
individually, there is a high percentage of very high risk category agreement, 
independent of the scoring system being compared. It is important to identify 
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individuals with high to very high CVD risk, and therefore a close analysis of these 
results is of great importance. When comparing lower and higher risk categories, we 
observed that a high proportion of the sample agreed in such conditions. This finding 
was more evident when comparing the FHS to the ASCVD risk score. However, many 
individuals categorized with higher FHS were also categorized with lower SCORE, and 
ASCVD categories. FHS may overestimate CHD risk. When comparing SCORE to 
ASCVD, more than half of patients with a moderate SCORE are attributed a high/very 
high risk category with ASCVD. These results for “underestimation” for the SCORE 
risk were already expected, as this predicts fatal outcomes better.  
The DAD score, which is an equation designed specifically for HIV-infected patients 
[25], has been compared to other CVD risk scores. FHS-CHD also overestimates the 
risk when compared to this last mentioned scoring system [26-27]. On the other hand, 
the DAD study [22] found that FH may slightly underestimate MI risk on patients on 
cART. When ASCVD is compared to the DAD score, a better concordance is obtained 
than that of FHS or SCORE [23-26]. In fact, a recent long cohort study has suggested 
that ASCVD may be the better myocardial infarction risk predictor for the HIV 
population, even when compared to the DAD score (unpublished observation; Heidi M. 
Crane et al). However, differences of the outcomes predicted by each scoring system 
have to be taken into consideration every time we draw a conclusion on this matter. In 
our sample, no conclusion can be taken regarding which scoring system is the best CVD 
predictor, as we have no information about the outcome.  
The majority of patients with MS are in the high/very high risk category, independent of 
the compared equation. However, concordance was not very high. We cannot know 
whether MS may, or may not be comparable to cardiovascular disease scoring systems, 
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however we can be more aware when MS is diagnosed, and a closer watch of these 
patients is needed. The high prevalence of higher CVD risk categories in our sample 
may be explained by the high prevalence of metabolic syndrome. De Socio et al. [21] 
reported that a clear correlation exists between estimated FHS and observed MS, and 
that lipodystrophy and a CD4 cell count >500 cells/m
3
 are associated with the 
coexistence of a high/very high FHS and the presence of this syndrome.    
It is hard to compare studies, owing to the different methodological designs, different 
age means, or other population characteristics that may importantly influence the 
results.  
The aim of this study was never to determine conclusions that are representative sample 
of HIV population, which it is not, but rather to compare results between different fat 
distribution groups. Cardiovascular risk factors have cumulative effects throughout a 
lifetime, and we measured risk factors at one point in time.  
This study was performed in a department highly experienced in the assessment of 
metabolic and body fat abnormalities in HIV-infected patients. Clinical assessment was 
always executed by the same practitioner (PF). To our knowledge, this is one of the first 
studies to evaluate whether any differences exist in cardiovascular risk factors and 10-
year risk, with regards to four different groups of fat distribution. We point out that 
patients with mixed forms of lipodystrophy are at higher 10-year CVD risk, and that 
those with isolated central fat accumulation have important modifiable CVD risk 
factors, which require a close watch with regards to CVD risk. Our study also suggests 
that independent of the scoring system used, at least the majority of the high to very 
high risk categorized individuals are identified.  
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 Conclusions 
There is a high percentage of 10-year cardiovascular disease risk in this sample, 
independent of the scoring system, or of fat body distribution. HIV-infected patients 
with mixed forms of lipodystrophy deserve special attention, as they are at higher CVD 
risk. Measures need to be applied to reduce CVD risk factors, as most of them are 
modifiable or treatable, and apparently they are the major influence for CVD risk in 
these individuals. 
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Table 1: Variables and outcomes of different CVD risk scores and MS  
 FHS-CHD SCORE ASCVD MS 
(at least 3 of the 5 criteria) 
Age 30-74 40-65 40-79  
Gender        
Ethnics      
Total cholesterol (TC)        
High-density lipoprotein 
cholesterol (HDL) 
      
Low-density lipoprotein 
cholesterol (LDL) 
     
Hypertriglyceridemia      
Systolic blood pressure        
Dyastolic blood pressure        
Hypertension      
Hypertension treatment       
Smoking        
Diabetes   ~ high/very 
high risk 
   
Glucose      
BMI      
Central obesity      
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Low risk 0-1 CVD risk 
factors 
<1% <5%  
Intermediate risk <10% ≥1 but <5% ≥5 but 
<7,5% 
 
High risk 10-20% ≥5% but 
<10% 
≥7.5% but 
<10% 
 
Very high risk >20% ≥10% ≥10%  
Coronary heart disease (angina 
pectoris, myocardial infarction, 
death due to CHD) 
     
CV fatal events (aortic aneurysm, 
myocardial infarction, stroke) 
     
Atherosclerotic CVD (nonfatal 
myocardial infarction, fatal 
coronary heart disease and 
nonfatal or fatal stroke) 
     
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Table 2: Sample characteristics according to the presence or absence of clinical 
lipodystrophy and/or abdominal prominence  
 No 
lipodystrophy  
Isolated 
central fat 
accumulation  
Isolated 
lipoatrophy  
Mixed forms 
of 
lipodystrophy  
p 
n (%) 93 (16.3) 179 (31.3) 151 (26.4) 149 (26.0)  
Age [years, mean 
(sd)] 
43.8 (11.7) 47.8 (12.1) 44.7 (9.6) 52.7 (10.9) <0.001 
Gender [n,(%)] 
Male  
Female  
 
73 (78.5) 
20 (21.5) 
 
99 (55.3) 
80 (44.7) 
 
135 (89.4) 
16 (10.6) 
 
95 (63.8) 
54 (36.2) 
<0.001 
 
Duration of HIV 
infection [years, 
median (IQR)] 
7.0 (6.0) 6.0 (7.0) 10.0 (7.0) 9.0 (6.0) <0.001 
cART [years, 
median (IQR)] 
5.0 (8.0) 4.0 (7.0) 9.0 (6.0) 8.0 (6.0) <0.001 
CD4 cell count 
[cells/mm³, 
median (IQR)] 
401.0 (325.0) 460.0 (332.0) 509.0 
(357.0) 
557.0 (404.0) 0.002 
HIV RNA [n (%)] 
≥ 50 copies/mL 
(n=75) 
 
15 (23.4) 
49 (76.6) 
 
32 (27.4) 
85 (72.6) 
 
14 (11.1) 
112 (88.9) 
 
14 (13.3) 
91 (86.7) 
0.003 
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<50 copies/mL  
CDC [n (%)]  
A  
B  
C  
 
32 (52.5) 
5 (8.2) 
 
24 (39.3) 
 
58 (56.9) 
1 (1.0) 
43 (42.2) 
 
67 (55.8) 
0 (0.0) 
53 (44.2) 
 
54 (54.5) 
1 (1.0) 
44 (44.4) 
0.061 
ART [n (%)] 
IP  
NNRTI  
NRTI  
 
49 (58.3) 
35 (41.5) 
78 (91.8) 
 
87 (54.0) 
64 (40.5) 
147 (91.3) 
 
74 (51.0) 
73 (50.7) 
144 (99.3) 
 
68 (48.2) 
70 (50.0) 
134 (94.4) 
 
0.484 
0.180 
0.004 
Alcohol (n,%)  37 (41.1) 67 (40.6) 69 (47.9) 60 (40.8) 0.531 
Smoking history 
[n (%)]  
Never 
Active 
Former 
 
29 (32.6) 
47 (52.8) 
13 (14.6) 
 
86 (52.1) 
47 (28.5) 
32 (19.4) 
 
42 (29.3) 
81 (56.3) 
21 (14.6) 
 
67 (46.2) 
41 (28.3) 
37 (25.5) 
<0.001 
Personal history of 
CVD [n (%)]  
7 (7.6) 20 (11.6) 8 (5.4) 22 (14.8) 0.043 
Familiar history of 
CVD [n (%)]  
35 (40.2) 68 (41.7) 63 (43.4) 68 (46.9) 0.737 
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Statins [n (%)]  13 (14.1) 50 (27.9) 33 (22.0) 51 (34.2) 0.003 
Fibrates [n (%)]  14 (15.2) 34 (19.0) 45 (30.0) 48 (32.2) 0.002 
Oral antidiabetic 
[n (%)]  
7 (7.7) 29 (16.2) 16 (10.7) 32 (21.5) 0.010 
Insulin [n (%)]  8 (8.7) 4 (2.2) 13 (8.7) 7 (4.7) 0.039 
SBP [mmHg, 
median (IQR)] 
120.0 (24.0) 126.0 (30.0) 115.5 
(29.0) 
130.0 (20.0) <0.001 
DBP [mmHg, 
median (IQR)] 
70.0 (17.0) 80.0 (14.0) 71.5 (20.0) 80.0 (15.0) <0.001 
Hypertension [n 
(%)]  
22 (23.7) 65 (36.3) 42 (28.2) 72 (48.3) <0.001 
Anti-hypertensive 
therapy [n (%)]  
9 (9.8) 37 (20.7) 21 (14.0) 46 (31.1) <0.001 
Weight [kg, mean 
(sd)] 
64.0 (10.1) 80.9 (16.1) 61.6 (9.9) 73.9 (12.9) <0.001 
BMI [(kg/m2), 
mean (sd)] 
22.9 (2.7) 29.7 (4.7) 21.8 (2.9) 27.2 (3.7) <0.001 
Waist 
circumference 
[cm, mean, (sd)] 
83.4 (7.9) 102.8 (11.3) 83.0 (7.1) 98.8 (8.3) <0.001 
Hip circumference 
[cm, mean, (sd)]  
92.6 (4.8) 104.0 (9.0) 88.8 (5.4) 96.3 (7.5) <0.001 
Waist/hip 
circumference 
ratio  
0.91 (0.07) 0.99 (0.08) 0.94 (0.06) 1.03 (0.07) <0.001 
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Total cholesterol 
(TC) mg/dL, 
mean (sd) 
213.5 (57.9) 225.4 (56.1) 208.3 
(54.4) 
222.4 (59.2) 0.032 
LDL-cholesterol 
(LDL) mg/dL, 
mean (sd) 
131.7 (47.5) 137.3 (44.6) 120.9 
(42.6) 
135.3 (49.4) 0.009 
HDL-cholesterol 
(HDL) mg/dL, 
mean (sd) 
48.4 (13.8) 48.8 (14.0) 44.3 (13.7) 46.4 (12.6) 0.016 
Triglycerides (TG) 
mg/dL, median 
(IQR) 
157.0 (133.0) 170.0 (136.0) 204.0 
(225.0) 
198.0 (165.0) 0.009 
Glucose 0’ 
mg/dL, median 
(IQR) 
90.0 (21.0) 97.0 (28.0) 94.0 (27.0) 100.0 (37.0) <0.001 
HbA1C %, 
median (IQR) 
5.15 (1.0) 5.40 (1.0) 5.30 (1.0) 5.60 (1.0) <0.001 
Diabetes [n (%)]  18 (19.6) 42 (23.5) 34 (22.7) 44 (29.7) 0.286 
Metabolic 
syndrome [n (%)]  
20 (29.0) 63 (65.6) 46 (35.7) 60 (66.7) <0.001 
Framingham [n 
(%)]  
Low risk (0-1 
 
 
 
 
 
 
 
 
<0.001 
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CVD risk factors) 
Moderate risk (≥2 
CVD risk factors 
and a 10-year 
CVD risk <10%) 
High risk (≥2 
CVD risk factors 
and a 10-year 
CVD risk 10-20%) 
Very high risk 
(CHD or CHD 
equivalent or ≥2 
CVD risk factors 
and a 10-year 
CVD risk >20%) 
8 (9.3) 
 
42 (48.8) 
 
 
18 (20.9) 
 
 
18 (20.9) 
8 (5.0) 
 
71 (44.7) 
 
 
34 (21.4) 
 
 
46 (28.9) 
1 (0.7) 
 
70 (50.0) 
 
 
33 (23.6) 
 
 
36 (25.7) 
2 (1.4) 
 
44 (31.0) 
 
 
30 (21.1) 
 
 
66 (46.5) 
SCORE [n (%)]   
Low risk  (10-year 
CVD risk <1%) 
Moderate risk (10-
year CVD risk ≥1 
but <5%) 
High risk (diabetes 
 
9 (17.6) 
 
24 (47.1) 
 
 
31 (29.5) 
 
27 (25.7) 
 
 
22 (24.7) 
 
34 (38.2) 
 
 
19 (17.6) 
 
41 (38.0) 
 
0.194 
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without any other 
CVD risk factor or 
10-year CVD risk 
≥5 but <10%) 
Very high risk 
(previous CVD or 
diabetes with other 
CVD risk factors 
or 10-year CVD 
risk ≥10) 
3 (5.9) 
 
 
15 (29.4) 
 
 
6 (5.7) 
 
 
41 (39.0) 
2 (2.2) 
 
 
31 (34.8) 
4 (3.7) 
 
 
44 (40.7) 
ASCVD score [n 
(%)]   
Low risk (10-year 
CVD risk <5%) 
Moderate risk (10-
year CVD risk ≥5 
but <7.5%) 
High risk (10-year 
CVD risk ≥7.5% 
but <10%) 
Very High risk 
(10-year CVD risk 
 
 
9 (25.7) 
 
9 (25.7) 
 
4 (11.4) 
 
13 (37.1) 
 
 
27 (35.5) 
 
10 (13.2) 
 
6 (7.9) 
 
33 (43.4) 
 
 
19 (24.7) 
 
20 (26.0) 
 
6 (7.8) 
 
32 (41.6) 
 
 
18 (19.4) 
 
16 (17.2) 
 
8 (8.6) 
 
51 (54.8) 
0.244 
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≥ 10%) 
CL – clinical lipodystrophy; AP – abdominal prominence; IP – Protease Inhibitors; NNRTI – Non-
Nucleoside Reverse Transcriptase Inhibitors; NRTI – Nucleoside Reverse Transcriptase Inhibitors; SBD 
– systolic blood pressure; DBP – diastolic blood pressure; BMI – body mass index; TC – total 
cholesterol; LDL – low-density lipoproteinHbA1c – glycated hemoglobin; CVD – cardiovascular disease; 
ASCVD – atherosclerotic cardiovascular disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
Table 3: Proportions of CVD risk classifications in different CVD risk scores for the 
whole sample.  
 FHS SCORE ASCVD 
Low (n,%) 3.6 (19) 22.9 (81) 26.0 (73) 
Intermediate (n,%) 43.1 (227) 35.7 (126) 19.6 (55) 
High (n,%) 21.8 (115) 4.2 (15) 8.5 (24) 
Very high (n,%) 31.5 (166) 37.1 (131) 45.9 (129) 
Total (n,%) 527 (100) 353 (100) 281 (100) 
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Table 4: Agreement of low/moderate/high and very high risk categories within MS.  
 With MS 
 
Without MS 
 
Kappa 
coefficient 
p 
FHS 
Low/moderate/high 
Very high 
 
76 (41.1) 
109 (58.9) 
 
148 (79.6) 
37 (20.4) 
0.385 <0.001 
SCORE 
Low/moderate/high 
Very high 
 
60 (42.0) 
83 (58.0) 
 
86 (77.5) 
25 (22.5) 
0.343 <0.001 
ASCVD 
Low/moderate/high 
Very high 
 
29 (27.6) 
76 (72.4) 
 
63 (61.8) 
39 (38.2) 
0.342 
 
<0.001 
FHS – Framingham Score; MS – Metabolic syndrome 
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Table 5: Agreement proportions (n, %) for the whole sample  
 Kappa 
coefficient 
FHS 
SCORE Low risk Moderate risk High risk Very high risk  
Low risk  1 (50.0) 67 (61.5) 12 (11.9) 0 (0.0)  
Moderate risk 1 (50.0) 26 (23.9) 62 (61.4) 37 (28.5)  
High risk 0 (0.0) 4 (3.7) 3 (3.0) 8 (6.2)  
Very high risk 0 (0.0) 12 (11.0) 24 (23.8) 85 (65.4) 0.095 
FHS 
ASCVD  Moderate risk High risk Very high risk  
Moderate risk  15 (93.8) 39 (50.0) 1 (0.9)  
High risk  1 (6.3) 19 (24.4) 4 (3.5)  
Very high risk  0 (0.0) 20 (25.6) 108 (95.6) 0.475 
SCORE 
ASCVD Low risk Moderate risk High risk Very high risk  
Low risk 53 (84.1) 14 (12.5) 0 (0.0) 6 (8.3)  
Moderate risk 8 (12.7) 38 (33.9) 0 (0.0) 7 (9.7)  
High risk 2 (3.2) 18 (16.1) 0 (0.0) 4 (5.6)  
Very high risk 0 (0.0) 42 (37.5) 7 (100.0) 55 (76.4) 0.408 
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